Description of Tykerb
Brand Name : Tykerb Composition : Lapatinib Manufactured by : Novartis India Ltd. Strength : 250 mg Dosage Form : Tablets Packing : Pack of 30 Tablets ABOUT TYKERB Tykerb is a anticancer drugs which inhibits the growth and spreadness of cancer cells throughout the body. Tykerb is indicated for metastatic breast cancer and spread after use of other cancer medicines.
Pharmacology of Tykerb
PHARMACODYNAMIC MECHANISM OF ACTION: Tykerb is a type of classification called kinase inhibitor. Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase Speciality of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors with a dissociation half-life of â‰¥300 minutes. Tykerb prevents ErbB-forced tumor cell growth in vitro and in various animal models. An additive effect was demonstrated when Tykerb and 5-fluracil were used in combination in the 4 tumor cell lines tested. The growth interferes the effects of Tykerb were examined in trastuzumab-conditioned cell lines. Tykerb maintained specific activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing intracellularly. Hormone receptor-positive breast cancer cells (with ER [Estrogen Receptor] and/or PgR [Progesterone Receptor]) that coexpress the HER2 bear to be protection against established endocrine therapies. Simultaneously hormone receptor-positive breast cancer cells that initially lack EGFR or HER2 unrecalled these receptor proteins as the tumor becomes resistant to endocrine therapy. PHARMACOKINETIC ABSORPTION: Incomplete and variable absorps from the GI tract. After administration peak plasma concentration is approx 4hrs.bioavailability is 95%. While administrate with food will increase the systemic exposure. DISTRIBUTION: Plasma protein binding is 99% METABOLISM: Evertor Metabolized mainly by CYP3A4 and CYP3A5. ELIMINATION: Excreted dose through feces more than 14% and <2% of the dose via urine. Eliminated half life is 24hrs.
Indication of Tykerb
Tykerb is used with combination of capecitabine for the treatment of advanced breast cancer after the failure of other cancer medicine.Tykerb is also used with letrozole combination to treat postmenopausal women with hormone receptor positive metastatic breast cancer.
Dose & Dosage's of Tykerb
Tykerb dosing for HER2 positive metastatic breast cancer ( with xeloda) is 1250mg once daily for 1-21days continuously repeating. Combination with femara is 1500mg orally once a day continuosly once daily every day. Administrate Tykerb on an empty stomach(1hr before or 1hr after).
Side Effects of Tykerb
Common side effect: Back ache; loose stools; dry skin; fingernail or toenail changes; head pain; difficult in digestion; decreased appetite; mild hair loss or thinning; mouth ulcers; nausea; nosebleed; redness and tingling of the hands and feet; tiredness; difficult in sleeping; vomiting. Serious side effect: . stomach pain; severe weakness; dyspnea; unusual bruising or bleeding; unusual itching; yellowing of the eyes or skin;.pain in chest; dark urine; dizziness or light-headedness; fast or irregular heartbeat; pale stools; persistent loss of appetite; severe or persistent cough; severe or persistent diarrhea, nausea, vomiting and skin allergy like itching,rashes,swelling in mouth,face,lip or tongue.
Contraindication of Tykerb
Tykerb is contraindicated to hypersensitivity condition. Tablet should avoid during condition of allergic reaction, breastfeeding,pregnant.
Drug Interaction of Tykerb
Tykerb regimen interact with Artemether,Etravirine,Pazopanib,Tracrolimus,Telithromycin,Topotecan,Tramadol,Tretinoin, Voriconazole,Ziprasidone. May increase risk of side effects and will not work properily and effect of tykerb may changes.
Precaution of Tykerb
Tykerb should avoided If you are allergic to lapatinib Before taking this Tykerb, should consult doctor whether itâ€™s safe to use or not:as follows: hepatic problem, cardio disease, an electrolytic imbalance. Tykerb should not prefer during pregnancy because it harm the unborn baby or cause birth defects. Avoid breast feeding during Tykerb treatment, it is not known whether Lapatinib passes into breast milk.
Usage & Safety profile of Tykerb Pregnancy & Lactation
Tykerb should be used, if drug benefit confirm the specific risk of fetus. There is no sufficient and well tolerated studies of Tykerb in pregnant women. Tykerb is unknown effect on human pregnancy. Do not become pregnant while receiving treatment withTykerb.
Storage of Tykerb
Avoid using of Tykerb after expiry date. Keep away from the children. Store at 25-300C. Dispose of medicine should consult with pharmacist.for proper dispose of chemo drugs.